featured
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10
J. Clin. Oncol 2019 Aug 23;[EPub Ahead of Print], J Abraham, AJ Montero, RC Jankowitz, MA Salkeni, JH Beumer, BF Kiesel, F Piette, LM Adamson, RJ Nagy, RB Lanman, J Sperinde, W Huang, CJ Allegra, A Srinivasan, Y Wang, KL Pogue-Geile, PC Lucas, SA JacobsFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.